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Abstract
Background/aims: Current in vitro drug sensitivity tests have limitations and disadvantages. This study investigated the use
of gene expression data to predict the sensitivity of pancreatic cancers to gemcitabine. Materials and methods: Cancer cells
isolated from 14 pancreatic cancer patients were tested in vitro for gemcitabine sensitivity using the collagen droplet drug
sensitivity test (CD-DST). On the basis of this test, 9 of the 14 cancers were identified as either gemcitabine-sensitive or
gemcitabine-resistant. Total RNA was extracted from each of those nine cancers and used as a template to synthesize Cy3-
labeled cDNA. Pancreatic RNA extracted from six normal individuals was used as a control. Labeled probes were
hybridized to an Atlas Glass Human 1.0 Microarray chip, after which the chips were washed and scanned, and the data were
analyzed using Microsoft Excel-embedded software. The expression profiles of selected genes were confirmed using real-
time PCR analysis. Results: Statistical analysis of the microarray data showed that four genes were differentially expressed in
gemcitabine-sensitive cancers: microsomal glutathione S-transferase 1 (GSTT1), topoisomerase II alpha (TOP2A), caspase
3, and ATP-binding cassette and subfamily C member 2 (ABCC2). More than 20 other genes were additionally identified
as possible candidate genes associated with drug resistance. Conclusions: Expression of drug resistance-related genes
appeared to predict whether a cancer was gemcitabine-sensitive or -resistant. Further study will enable a drug resistance
scoring system to be established on the basis of gene expression. Such a system will allow more efficient application of
chemotherapy.
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Introduction
Treatment of carcinoma of the exocrine pancreas is a
major problem, with approximately 80% of patients
presenting with unresectable disease due to metas-
tases and/or local invasion [1]. Despite many ad-
vances in solid tumor therapies over recent decades,
unresectable pancreatic cancer continues to have a
median survival time of only 36 months. The
development of gemcitabine, a deoxycytidine analog
related to cytarabine, has prompted renewed interest
in developing cytotoxic therapies for pancreatic can-
cer. Although gemcitabine is a well-tolerated drug
and ideal for palliation of symptomatic cancer, the
efficacy rates remain at only 2030%. However, in
some cases tumors respond well to this treatment and
patients experience long survival times.
Since the characteristics of pancreatic cancer can
vary between individuals, chemotherapy should ide-
ally be tailored to each patient based on the nature of
their particular disease. The detection of potentially
chemo-sensitive tumors would significantly improve
response rates and facilitate the selection of effective
individualized regimens. Developing a method of
assessing the likely effectiveness of anticancer drugs
using resected or biopsied materials before treatment
is likely to avoid unnecessary treatment.
A number of tests to determine the chemo-
sensitivity of cancers to particular drugs have been
developed, including the nude mouse method, sub-
renal capsule assay (SRC), human tumor clonogenic
assay (HTCA), thymidine incorporation assay (TIA),
succinic dehydrogenase inhibition test (SDI test),
and the MTT assay [2]. However, none of these
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methods has been widely adopted in clinical practice
for various reasons, including low success rates for
primary culture, a large number of cells being
required for testing, difficulty in ruling out the effect
of contaminating fibroblasts, assays taking more than
a week, and skilled technicians being required.
Although Kobayashi et al. developed a collagen-gel
droplet embedded culture drug sensitivity test (CD-
DST) which avoids some of these shortcomings [3],
the method still requires significant quantities of
fresh tissue, usually more than 0.5 cm3.
Pancreatic cancers contain a high proportion of
fibroblasts and connective tissue, making it difficult to
obtain sufficient cancer tissue for primary culture
testing. The success rate of such cultures remains at
about 6080%. However, the development of micro-
array technology has made it possible to evaluate
pancreatic cancers using less tissue than required for
CD-DST, and with a higher success rate. Assersohn et
al. showed breast cancer gene expression profiles in
15% of patients using tissue from fine needle aspirates
and cDNA microarrays [4]. This microarray approach
is likely to become more common with increasingly
sensitive scanning techniques and validated amplifica-
tion techniques.
The present study investigated the use of gene
expression microarray technology for predicting the
chemo-sensitivity of pancreatic cancers.
Materials and methods
The study involved 14 patients with biopsy-proven
ductal adenocarcinoma of the pancreas admitted to
the Jichi Medical School Hospital (Tochigi, Japan)
between January 2001 and December 2003 (Table I).
We obtained approval from the ethics committee in
Jichi Medical University, and documented informed
consents from all patients. A laparotomy was per-
formed to obtain 2501000 mg of fresh pancreatic
cancer tissue.
CD-DST chemo-sensitivity tests were performed
using a human tumor cell primary culture system kit
(Primaster, Nitta Gelatin, Osaka, Japan) [5]. Briefly,
fresh surgical specimens from pancreatic cancers were
cut into small pieces aseptically and suspended in
Hanks’s balanced saline solution (HBSS). Cells were
dispersed by incubating tissue at 378C for 13 h in a
0.1% cell dispersion enzyme solution (EZ, Nitta
Gelatin). Cells were then centrifuged at 900 g for 3
min and the pellet was resuspended in PCM-1
medium (Nitta Gelatin), and the suspension filtered
through an 80 mm pore nylon mesh. After preliminary
culture in a collagen gel-coated flask in a CO2
incubator at 378C for 2448 h, 3/103 cells were
added to a 30 ml collagen gel droplet. Cells were
cultured in DF medium (Nissui Pharmaceutical Co.,
Tokyo, Japan) containing 10% fetal bovine serum
(Gibco BRL, Grand Island, NY, USA) with or with-
out 0.4 mg/ml gemcitabine for 24 h. Quantification of
the total volume of a cell colony, utilizing differences
in the growth morphologies of tumor cells and
fibroblasts, was determined using an image analysis
method [6]. The effect of gemcitabine was deter-
mined by calculating the ratio of the total colony
volume of cells with (T) and without (C) gemcitabine.
Cells with a T/C ratioB/50% were considered gemci-
tabine-sensitive, while those with a ratio/50% were
considered gemcitabine-resistant.
Gene expression profiles were evaluated using
microarray techniques. Briefly, purified total RNA
from frozen samples was isolated using Atlas Glass
Total RNA Isolation Kits (Clontech, Palo Alto, USA)
according to the manufacturer’s protocols. cDNA was
synthesized using BD Atlas PowerScript Fluorescent
Labeling Kits, and the resultant Cy3-labeled (Amer-
sham Pharmacia Biotech, Bucks, UK) double-
stranded cDNA was purified using QIAquick PCR
Table I. Profiles and chemo-sensitivities of the 14 pancreatic cancer patients.
Case
Age (years)
/gender Location Operation T/C ratio
Sensitive
/resistant Outcome
Duration
(M)
Chemotherapy
(M)
1 69/F Head PpPD 20.8 Sensitive Dead 15.9 7
2 62/M Head Unresectable None Unknown Dead 6.8 2
3 75/M Head Unresectable 74.4 Resistant Dead 14.3 8
4 61/M Head Unresectable 89.4 Resistant Dead 8.1 4
5 57/M Head Unresectable 76.2 Resistant Dead 15.5 7
6 59/F Head PpPD 64.6 Resistant Dead 15.6 11
7 70/F Body DP None Unknown Dead 11.3 2
8 78/F Head PpPD None Unknown Alive 41.2 12
9 72/F Head PpPD 76.2 Resistant Dead 10.1 5
10 75/F Tail DP None Unknown Dead 12.3 7
11 77/F Head PpPD 30 Sensitive Alive 42.0 12
12 64/M Head Unresectable 33.3 Sensitive Dead 16.1 11
13 65/M Body DP None Unknown Dead 24.4 12
14 74/M Head Unresectable 38.7 Sensitive Dead 16.6 10
PpPD, pylorus-preserving pancreatoduodenectomy; DP, distal pancreatectomy.
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Purification Kits (QIAGEN Valencia). Cy3-labeled
cDNA synthesized from a pool of normal pancreatic
RNA (BioChain Institute, Hay ward) was used as a
control. Cy3-labeled cDNA was hybridized to a BD
Atlas Glass Human 1.0 Microarray (Clontech) in a
water bath at 508C for 16 h. Chips were then washed
in four high-volume wash chambers (Clontech).
Using a GMS 418 Array Scanner (Takara, Tokyo)
and accompanying software, fluorescence intensities
for dyes Cy3 were determined and subtraction of local
background values for individual spots was per-
formed. The data were exported to Microsoft Excel
spreadsheets for analysis. To normalize for the
amount of total RNA on each chip, the sample/control
ratio for the expression of each gene was adjusted so
that the averaged Cy3:Cy3 ratio of seven house-
keeping genes was given the value of 1.0, and the
data then underwent log2 transformation. To identify
genes that were differentially expressed between drug-
sensitive and drug-resistant cancers, the Excel-em-
bedded statistical software ‘Analyse-it’ was used to
calculate the U and p values for the MannWhitney
analysis of each gene. A difference in gene expression
was considered significant if the p value wasB/0.05.
Differential expression of genes identified by micro-
array analysis was confirmed using real-time PCR
analysis and specific primers (Table II). Total RNA
used for the microarray analysis was also used for the
real-time PCR analysis. Primers were designed for the
genes of interest using GENETYX-WIN software
(Software Development Corporation, Tokyo, Japan),
and then PCR conditions were optimized for each pair
of primers (QuantiTec SYBR Green PCR Kit, Qiagen
KK, Tokyo, Japan). First strand cDNA was then
synthesized from 2 mg total RNA (Superscript First
Strand cDNA Synthesis Kit), and 1 ml RT-PCR
product was used in real-time PCR assays under
optimized reaction conditions. The 50 ml reaction
mixture comprised 25 ml SYBR Green PCR Master
Mix, 1 ml sense primer, 1 ml antisense primer, 1 ml
cDNA, 0.5 ml uracil-N-glycosylase, and 21.5 ml
RNase-free water. The real-time cycler conditions
were 508C for 2 min, 958C for 10 min, 948C for 15 s,
optimized annealing temperature for 30 s, 728C for 30
s, 50 cycles. b-Actin expression was used as a control
for normalizing the amounts of cDNA used. Reaction
products were analyzed using 2% agarose gel electro-
phoresis to confirm that the signals detected by the
GeneAmp PCR system 7700 (Perkin-Elmer Corpora-
tion, Foster City, USA) were from the expected
products. Three independent experiments were per-
formed.
Results
Using CD-DST, valid T/C ratios were obtained in 9
(64.3%) of the 14 cancers. A T/C ratio of 50% or less
was regarded as indicating that cells were gemcita-
bine-sensitive in vitro (Table III). On this basis, four
cancers were classified as gemcitabine-sensitive and
five as gemcitabine-resistant. However, an arbitrarily
assigned growth inhibition rate may not always reflect
clinical response because clinical response needs to be
based on log killed cells.
The log2 transformed Cy3/Cy3 signal data from
microarray analyses are shown in Table III (original
data are available to readers upon request by e-mail).
In all 1081 human genes contained in the Atlas Glass
Human 1.0 microarray, statistical analysis of the
microarray data identified 4 genes that were differen-
tially expressed between gemcitabine-sensitive and
-resistant cancers: microsomal glutathione S-transfer-
ase 1 (GSTT1), topoisomerase II alpha (TOP2A),
caspase 3, and ATP-binding cassette subfamily C
member 2 (ABCC2). Real-time PCR analyses con-
firmed the differential expression of these genes
(Figure 1). Paired Student’s t test showed no differ-
ence between the results of the two methods (p/
0.05). The fluctuations in mRNA expression between
the nine patients were found to be similar using either
analytical method.
For a further 22 genes, while statistical analysis
indicated that the difference in their expression be-
tween the two tissues was not significant, the p values
were close to 0.05. These genes were associated with
gemcitabine resistance and included cyclin-dependent
kinase inhibitor 1A, tumor protein p53 binding protein
2, activated p21cdc42Hs kinase, v-akt 2, insulin-like
growth factor 1 receptor, BCL2-interacting killer,
BCL2-like 2, BCL2-like 1, BCL2-related protein A1,
BCL2-interacting killer, topoisomerase I, APEX nu-
clease, transforming growth factor beta receptor II,
interleukin 6 receptor, cytochrome P450 subfamily
1 (dioxin-inducible), polypeptide 1, glutathione S-
transferase M1, transforming growth factor beta 1,
interleukin 8, insulin-like growth factor 1, nuclear
Table II. Sequences of primers used for PCR.
Gene Sense Antisense
b-Actin AATCTGGCACCACACCTTCTAC GCTTCTCCTTAATGTCACGCAC
GSTT1 GCATAAGGTGATGTTCCCTGTGT CGGTGCAAGGGTGAGGTTTC
ABCC2 GACATCTATCTTCTAGATGACC TAGATGGAGAACTTCACCTT
TOP2A GGGTAGCAATAATCTAAACCTC CCAGTTCTTCAATAGTACCCT
Caspase 3 TGAAGCTACCTCAAACTTCC CAGCATCACTGTAACTTGCT
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Table III. The log2 transformed Cy3/Cy3 signals of selected genes.
Sensitivity Case no. GSTT1 ABCC2 TOP2A Caspase 3
Case 1 0.18 /0.24 1.10 0.30
Case 11 1.25 /1.50 1.37 /1.25
Case 12 /0.19 0.38 /0.18 1.26
Case 14 0.16 /0.22 0.19 0.09
Case 3 1.20 0.29 /0.25 /2.54
Case 4 2.80 1.20 /2.33 /1.92
Case 5 1.72 1.87 /0.32 /1.78
Case 6 2.05 1.07 0.11 0.52
Case 9 3.58 2.45 /1.78 /1.77
p value B/0.05 B/0.05 B/0.05 B/0.05
Expressions of GSTT1, ABCC2, TOP2A, and caspase 3 between the gemcitabine-sensitive group and gemcitabine-resistant group are
significantly different (pB/0.05).
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Figure 1. Real-time PCR analyses (j) for confirmation of microarray data (I). The same RNA source was used for both microarray and
real-time PCR analyses. The Y-axis indicates the log2 transformed ratio of mRNA expression. Paired Student’s t test showed no difference
between the results of two methods (p/0.05).
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factor of kappa light polypeptide gene enhancer in
B-cells 2, ligase III and ligase I.
Discussion
Gemcitabine is a nucleoside analog which exhibits
metabolic characteristics that distinguish it from
related compounds and may explain its activity
against solid tumors. The active nucleotide effectively
accumulates at high concentrations in cells due to
both efficient phosphorylation and relatively slow
elimination. The diphosphate is a potent inhibitor of
ribonucleotide reductase, resulting in reduced deox-
ynucleotide pools. Decreased cellular concentrations
of deoxycytidine triphosphate permit more rapid
phosphorylation of gemcitabine and decrease the
metabolic clearance of gemcitabine nucleotides by
deoxycytidine monophosphate deaminase. Most im-
portantly, increasing the ratio of the cellular concen-
tration of gemcitabine triphosphate to deoxycytidine
triphosphate increases analog incorporation into
DNA, which is strongly associated with loss of cell
viability [7]. Gemcitabine alone or in combination
with other anticancer drugs has become a popular
regimen in pancreatic cancer.
Analysis of gene expression using cDNA chips
showed that four genes were differentially expressed
according to cells being either gemcitabine-sensitive
or -resistant. The four genes were identified as
GSTT1, TOP2A, caspase 3, and ABCC2. For each
gene, expression was associated with drug resistance.
These findings are in agreement with a report by
Scherf et al. indicating that gene expression profiles
may reflect drug sensitivity in cancer cells [8].
The cellular glutathione system (GSH) is a critical
component of the cytostatic detoxification pathway in
cells. GSTT1 is a member of a protein superfamily
that catalyzes the conjugation of reduced glutathione
to a variety of electrophilic and hydrophobic com-
pounds. The conjugate is less active and more water-
soluble, and it is excluded from the cell with the
participation of GS-X transporter proteins. GSTT1 is
claimed to play an important role in human carcino-
genesis [9,10]. Inhibitors of glutathione transferases
have been shown to enhance the cytotoxicity of
alkylating chemotherapeutic drugs in cultured cancer
cells otherwise resistant to this class of agent [11].
ABCC2 (MRP2) is a member of the ATP-binding
cassette (ABC) transporter superfamily, which is
involved in biliary, renal, and intestinal secretion of
numerous organic anions, including endogenous
compounds such as bilirubin and exogenous com-
pounds such as drugs and toxic chemicals [12]. This
protein is a member of the MRP subfamily that is
involved in multi-drug resistance [13].
TOP2A functions as the target for several antic-
ancer agents, and a variety of mutations in this gene
have been associated with drug resistance [14]. The
activity or quantity of this enzyme was lower in cell
lines resistant to topoisomerase II-inhibiting drugs. In
those lines, topoisomerase gene mutations were found
which were presumed to be the bases for the drug
resistance [15,16].
Caspase 3 cleaves and activates caspases 6, 7, and 9,
is processed by caspases 8, 9, and 10, and plays an
important role in apoptosis. A broad spectrum of
anticancer drugs used in the clinic has been shown to
activate apoptosis in vitro and in vivo [17,18]. Low
expression of caspase 3 has been shown to inhibit
chemotherapy-induced apoptosis [19].
In the present study, differences in the expression of
a further 22 genes almost reached statistical signifi-
cance. Many of these candidate genes have been
previously linked to drug resistance or carcinogenesis.
Some of the expressed sequence tags (ESTs) identi-
fied may represent genes that might be future targets
for novel anticancer drugs. Identification of further
differentially expressed genes will enable development
of an accurate drug response system (DRS) for
predicting the suitability of a particular cancer patient
for gemcitabine therapy [20].
Conclusions
Microarray evaluation has a number of distinct
advantages compared with the CD-DST method,
such as the requirements for less tissue and less time
(3 days), and the ease with which experiments can be
repeated if required. These advantages are of parti-
cular importance in pancreatic cancer analysis where
it is difficult to obtain large amounts of cancer tissue.
We believe that clinical application of such a DRS will
prevent cancer patients from undergoing ineffective
adjuvant chemotherapy.
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